[ad_1]
Professor Salim Yusuf, executive director of the Population Health Research Institute and Professor Emeritus of Medicine at McMaster University, said: “The current strategy for primary and secondary prevention of CVD [cardiovascular diseases] has only been modestly successful in most countries, including high-income countries.
“Even in these countries, fewer than half of patients with prior CVD, and fewer than 20 precent without prior CVD, receive effective preventive treatments.”
What’s more, polypill has been studied in independent large studies and trials, highlighting its “life-saving significance”.
Various publications also claim that the little tablet could slash the risk of heart attacks and strokes by 35 to 50 percent.
[ad_2]
